Literature DB >> 21376323

Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity.

Pajaree Lilitkarntakul1, Neeraj Dhaun, Vanessa Melville, Scott Blackwell, Dinesh K Talwar, Barbara Liebman, Takae Asai, Jennifer Pollock, Jane Goddard, David J Webb.   

Abstract

INTRODUCTION: Patients with chronic kidney disease (CKD) have increased risk of cardiovascular disease to which co-morbidity and associated conventional risk factors contribute. We hypothesised that arterial stiffness (AS) and endothelial dysfunction (ED), as surrogates of cardiovascular risk, would worsen as renal function declined even in patients without co-morbidity and that this would relate to emerging cardiovascular risk factors.
METHODS: Carotid-femoral pulse wave velocity (PWV), as a measure of AS, and flow-mediated dilatation (FMD) of the brachial artery, as a measure of ED, were assessed in CKD patients without established cardiovascular disease or diabetes mellitus.
RESULTS: PWV increased linearly as renal function declined (r(2) = 0.08, p < 0.01) whereas FMD was reduced only in patients with advanced kidney disease. In multivariable analysis, blood pressure was the major determinant of PWV and FMD. High-sensitivity C-reactive protein and asymmetric dimethylarginine, and isoprostanes and endothelin-1, were independent predictors of PWV and FMD, respectively. However, renal function did not independently predict either AS or ED.
CONCLUSIONS: These findings suggest that declining renal function, in the absence of significant co-morbidity, is associated with progressive arterial stiffness, but only patients close to dialysis exhibit endothelial dysfunction. Whilst blood pressure remains the major determinant of PWV and FMD, inflammation, oxidative stress and endothelin-nitric oxide balance contribute to cardiovascular risk, in this non-comorbid cohort.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376323     DOI: 10.1016/j.atherosclerosis.2011.01.045

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  32 in total

1.  Targeting Blood Vessel Stiffness to Protect Kidney Function.

Authors:  Neeraj Dhaun; David J Webb
Journal:  Clin J Am Soc Nephrol       Date:  2015-11-12       Impact factor: 8.237

2.  Lipoic acid attenuates the expression of adhesion molecules by increasing endothelial nitric-oxide synthase activity.

Authors:  Hong-Bo Jin; Yong-Bin Yang; Ying-Li Song; Yong-Chun Zhang; Yu-Rong Li
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

3.  Plasma Endothelin-1 and Risk of Death and Hospitalization in Patients Undergoing Maintenance Hemodialysis.

Authors:  Ping Li; Insa M Schmidt; Venkata Sabbisetti; Maria Clarissa Tio; Alexander R Opotowsky; Sushrut S Waikar
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-07       Impact factor: 8.237

4.  Do Cardiovascular Risk Factors and Severity and Complexity of Coronary Atherosclerosis Predict Aortic Pulse Pressure during Cardiac Catheterization?

Authors:  Hemal Bhatt; Dharmesh Sanghani; George Apergis; George Fernaine
Journal:  Int J Angiol       Date:  2015-06-23

5.  Relationship between kidney disease and endothelial function in peripheral artery disease.

Authors:  Karen C Chong; Christopher D Owens; Meyeon Park; Hugh F Alley; W John Boscardin; Michael S Conte; Warren J Gasper; S Marlene Grenon
Journal:  J Vasc Surg       Date:  2014-10-16       Impact factor: 4.268

6.  Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease.

Authors:  Ana Reis; Alisa Rudnitskaya; Pajaree Chariyavilaskul; Neeraj Dhaun; Vanessa Melville; Jane Goddard; David J Webb; Andrew R Pitt; Corinne M Spickett
Journal:  J Lipid Res       Date:  2014-11-25       Impact factor: 5.922

Review 7.  Arterial stiffness and chronic kidney disease: lessons from the Chronic Renal Insufficiency Cohort study.

Authors:  Raymond R Townsend
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-01       Impact factor: 2.894

Review 8.  Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.

Authors:  Donald E Kohan; David M Pollock
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

9.  Arterial Stiffness and Chronic Kidney Disease.

Authors:  Anne-Sophie Garnier; Marie Briet
Journal:  Pulse (Basel)       Date:  2016-03-01

10.  Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.

Authors:  Neeraj Dhaun; Vanessa Melville; Scott Blackwell; Dinesh K Talwar; Neil R Johnston; Jane Goddard; David J Webb
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.